ArticleGenetics research2026
Lipids and Lipid-Lowering Drugs With Risk of Intervertebral Disc Degeneration: A Mendelian Randomization Study.
Article in Genetics research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipids and Lipid-Lowering Drugs With Risk of Intervertebral Disc Degeneration: A Mendelian Randomization Study.Genetics research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined whether circulating lipid traits and lipid-lowering drug targets are causally associated with intervertebral disc degeneration (IVDD) using a Mendelian randomization (MR) framework. We analyzed summary-level data from genome-wide association studies (GWASs) covering apolipoproteins, lipid parameters, and IVDD. Univariable analysis revealed that inherently elevated high-density lipoprotein cholesterol (HDL-C) correlated with reduced IVDD susceptibility. By contrast, low-density lipoprotein cholesterol (LDL-C), triglycerides (TGs), apolipoprotein A-I (Apoa-I), and apolipoprotein B (Apob) did not remain significant after Bonferroni correction. Upon adjusting for body mass index (BMI) in a multivariable framework, the protective link between HDL-C and IVDD held strong, whereas LDL-C, TG, and Apob remained nonsignificant. Summary data-based MR and drug-target MR analyses further suggested a significant association between NPC1L1 gene expression and IVDD susceptibility. Overall, these results highlight the potential involvement of lipid pathways in disc degeneration and justify further biological and clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.